Trajectory of clinical symptoms in relation to amyloid chronicity

While it is generally appreciated that amyloid precedes symptomatic Alzheimer's disease (AD) by decades, a greater understanding of this timeline may increase prognostic accuracy, planning, and care of persons who are on the AD continuum.

[1]  R. Killiany,et al.  Trajectories of Cognitive Decline in Brain Donors With Autopsy-Confirmed Alzheimer Disease and Cerebrovascular Disease , 2022, Neurology.

[2]  Sterling C. Johnson,et al.  Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts , 2021, medRxiv.

[3]  S. Resnick,et al.  Vascular risk is not associated with PET measures of Alzheimer's disease neuropathology among cognitively normal older adults. , 2021, Neuroimage. Reports.

[4]  A. Fagan,et al.  Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET , 2021, Neurology.

[5]  David T. Jones,et al.  Relationships between β-amyloid and tau in an elderly population: An accelerated failure time model , 2021, NeuroImage.

[6]  Philip S. Insel,et al.  Time between milestone events in the Alzheimer's disease amyloid cascade , 2020, NeuroImage.

[7]  Naaheed Mukadam,et al.  Dementia prevention, intervention, and care: 2020 report of the Lancet Commission , 2020, The Lancet.

[8]  Cassidy M. Fiford,et al.  CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease , 2020, Neurobiology of Aging.

[9]  S. Murphy,et al.  Commission , 2019, Some Glad Morning.

[10]  Sterling C. Johnson,et al.  Amyloid duration is associated with preclinical cognitive decline and tau PET , 2019, bioRxiv.

[11]  M. Carrillo,et al.  Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia , 2019, JAMA.

[12]  Sterling C. Johnson,et al.  In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls , 2018, The Journal of Nuclear Medicine.

[13]  Miia Kivipelto,et al.  Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease , 2018, Nature Reviews Neurology.

[14]  C. Jack,et al.  The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. , 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.

[15]  Lilah M. Besser,et al.  A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. , 2018, Journal of Alzheimer's disease : JAD.

[16]  Sterling C. Johnson,et al.  The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions , 2017, bioRxiv.

[17]  Kimberly D. Mueller,et al.  Use of the Quick Dementia Rating System (QDRS) as an Initial Screening Measure in a Longitudinal Cohort at Risk for Alzheimer’s Disease , 2017, Journal of Alzheimer's disease reports.

[18]  S. Kremen,et al.  Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care , 2016, Alzheimer's & dementia.

[19]  P. Pasqualetti,et al.  Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study. , 2016, JAMA neurology.

[20]  K. Arfanakis,et al.  NEUROPATHOLOGIC CORRELATES OF WHITE MATTER HYPERINTENSITIES IN A COMMUNITY COHORT OF OLDER ADULTS , 2016, Alzheimer's & Dementia.

[21]  Nick C Fox,et al.  White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network , 2016, Annals of neurology.

[22]  Jerry L. Prince,et al.  Individual estimates of age at detectable amyloid onset for risk factor assessment , 2016, Alzheimer's & Dementia.

[23]  J. Galvin.  The Quick Dementia Rating System (QDRS): A rapid dementia staging tool , 2015, Alzheimer's & dementia.

[24]  D. Y. Lee,et al.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.

[25]  A. Brickman,et al.  Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence , 2015, Neurobiology of Aging.

[26]  C. Jack,et al.  Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly , 2015, Brain : a journal of neurology.

[27]  Sterling C. Johnson,et al.  Amyloid burden and neural function in people at risk for Alzheimer's Disease , 2014, Neurobiology of Aging.

[28]  Keith A. Johnson,et al.  Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association , 2013, The Journal of Nuclear Medicine.

[29]  Florian Auer,et al.  White matter hyperintensities predict amyloid increase in Alzheimer's disease , 2012, Neurobiology of Aging.

[30]  Bernhard Hemmer,et al.  An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis , 2012, NeuroImage.

[31]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[32]  W. Chan,et al.  Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database. , 2010, Archives of neurology.

[33]  Daniel S Nagin,et al.  Group-based trajectory modeling in clinical research. , 2010, Annual review of clinical psychology.

[34]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[35]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[36]  L. Thal,et al.  Clinical Dementia Rating training and reliability in multicenter studies , 1997, Neurology.